Amsterdam Cardiovascular Sciences

TrimetaziDine as a Performance-enhancING drug in heart failure with preserved ejection fraction (DoPING-HFpEF): rationale and design of a placebo-controlled cross-over intervention study: rationale and design of a placebo-controlled cross-over intervention study

van de Bovenkamp, A. A., Bakermans, A. J., Allaart, C. P., Nederveen, A. J., Kok, W. E. M., van Rossum, A. C. & Handoko, M. L., 1 Jun 2020, In: Netherlands Heart Journal. 28, 6, p. 312-319 8 p.

Research output: Contribution to Journal › Article › Academic › peer-review

Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction

van de Bovenkamp, A. A., van Rossum, A. C. & Handoko, M. L., 19 Mar 2020, In: The New England journal of medicine. 382, 12, p. 1180-1183 4 p.

Research output: Contribution to Journal › Letter › Academic › peer-review

Hemodynamic Effects of Pulmonary Arterial Hypertension-Specific Therapy in Patients With Heart Failure With Preserved Ejection Fraction and With Combined Post- and Precapillay Pulmonary Hypertension

Huis in ’t Veld, A. E., Oosterveer, F. P. T., de man, F. S., Marcus, J. T., Nossent, E. J., Boonstra, A., van Rossum, A. C., Vonk Noordegraaf, A., Bogaard, H. J. & Handoko, M. L., Jan 2020, In: Journal of Cardiac Failure. 26, 1, p. 26-34 9 p.

Research output: Contribution to Journal › Article › Academic › peer-review

Pathophysiological analysis of serially measured plasma biomarkers, remote monitoring and clinical events, in symptomatic patients with moderate to severe chronic heart failure

Allach, Y., de Jong, M. B. L., Clephas, P. R. D., Kamar, S. A., Brunner-la Rocca, H. P., Handoko, M. L., van Halm, V. P., Kok, W. E. M., Asselbergs, F. W., van Kimmenade, R. R. J., Beeres, S. L. M. A., Rienstra, M., Szymanski, M. K., de Boer, R. A., Kardys, I. & Brugts, J. J., 1 Aug 2026, In: IJC Heart and Vasculature. 65, 101970.

Research output: Contribution to Journal › Article › Academic › peer-review

Safety, pharmacokinetics, and exploratory efficacy of the oral ghrelin receptor agonist AC01 in heart failure with reduced ejection fraction (GOAL-HF1): a randomised, double-blind, placebo-controlled, phase 1b/2a study

Lund, L. H., Barandiarán Aizpurua, A., Bollano, E., Braun, O., Brouwer, J. L. P., Buikema, J. W., Cannata, A., Gardner, R. S., Handoko, M. L., Lang, C. C., Metra, M., Sinagra, G., Thorvaldsen, T., van der Boon, R. M. A., van Essen, B. J., Shah, S. J., Voors, A. A., Lam, C. S. P., Pitt, B. & Solomon, S. D. & 10 others, Hage, C., Stahlberg, M., Bernareggi, A., Gordon, A., del Sole, M., Rosendahl, E., Stromberg, P., Westerberg, G., Edfors, R. & Petrie, M. C., 18 Jul 2026, In: The Lancet. 408, 10551, p. 248-262 15 p.

Research output: Contribution to Journal › Article › Academic › peer-review

De invloed van obesitas op de diagnostiek van hartfalen

Translated title of the contribution: The impact of obesity on natriuretic peptide cut-off values for the diagnosis of heart failureTaha, K. & Louis Handoko, M., 1 Jun 2026, In: Nederlands tijdschrift voor geneeskunde. 170, 6, p. 68-70 3 p., D8887.

Research output: Contribution to Journal › Comment / Letter to the editor › Professional